The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 23, 2018

Filed:

Nov. 02, 2012
Applicant:

Zhejiang Hisun Pharmaceutical Co., Ltd., Taizhou, Zhejiang, CN;

Inventors:

Ravindra K Pandey, East Amherst, NY (US);

Yihui Chen, Amherst, NY (US);

Hua Bai, Taizhou, CN;

Zhenliang Chen, Taizhou, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 41/00 (2006.01); C07D 487/22 (2006.01); A61K 47/48 (2006.01); A61K 49/00 (2006.01); A61K 31/7072 (2006.01); A61K 31/337 (2006.01); A61K 31/7064 (2006.01); A61K 31/7068 (2006.01); A61K 31/706 (2006.01);
U.S. Cl.
CPC ...
A61K 41/0057 (2013.01); A61K 31/337 (2013.01); A61K 31/7072 (2013.01); A61K 41/0071 (2013.01); A61K 47/48061 (2013.01); A61K 47/48092 (2013.01); A61K 49/0036 (2013.01); C07D 487/22 (2013.01); A61K 31/706 (2013.01); A61K 31/7064 (2013.01); A61K 31/7068 (2013.01);
Abstract

A targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof is provided, which improves the selectivity of photosensitizers to tumor cells, has better tolerance, can reach maximum blood concentration in 24 hours, has a bigger conjugated system, a longer absorption wavelength and an advantage in treating depth tumors; the wavelength area does not need to consume much energy of a light-output device and even LEDs can be used, which render PDT more practical and economical. The targeting thymidine kinase photosensitizer can be used for diagnosis and for treating prostatic carcinoma via the guidance of fluorescence imaging. The pharmaceutical composition uses a combination of a chemotherapeutic agent and the targeting thymidine kinase photosensitizer, which further improves the therapeutic effect of the PDT method, expands the application range for tumors and has good effects on metastatic tumors as well.


Find Patent Forward Citations

Loading…